Erasca Q3 2022 net loss $35.5M; cash $365.5M funds ops into H2 2024

Erasca, Inc.

2022-Q3 EPS reported -$0.90

Net loss $35.5M ($0.29/sh) vs $46.1M ($0.46/sh) in Q3 2021; R&D spend $28.2M.
Cash, cash equivalents & marketable securities $365.5M as of Sep 30, 2022; expects to fund operations into H2 2024.
Positive preliminary monotherapy data for ERAS-007 and ERAS-601: 23% response in RAS/MAPK-altered non-CRC solid tumors.
Entered CTCSAs with Lilly (cetuximab + ERAS-601) and Pfizer (palbociclib + ERAS-007); strategic R&D collaboration with MD Anderson.
Upcoming milestones: IND for CNS-penetrant KRAS G12C inhibitor ERAS-3490 by year-end 2022; combo data for ERAS-007/601 in H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Erasca, Inc. reported financial results for the fiscal quarter ended September 30, 2022.

Period: the fiscal quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Erasca, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023851

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.